Search Results - "Zhao, Jiuda"

Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development by Shen, Guoshuang, Zheng, Fangchao, Ren, Dengfeng, Du, Feng, Dong, Qiuxia, Wang, Ziyi, Zhao, Fuxing, Ahmad, Raees, Zhao, Jiuda

“…Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor…”
Get full text

The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis by Huo, Xingfa, Li, Jinming, Zhao, Fuxing, Ren, Dengfeng, Ahmad, Raees, Yuan, Xinyue, Du, Feng, Zhao, Jiuda

“…The role of capecitabine in neoadjuvant and adjuvant chemotherapy for early-stage triple-negative breast cancer (TNBC) is highly controversial. Our…”
Get full text

Development of Tumor Markers for Breast Cancer Immunotherapy by Fang, Qianqian, Shen, Guoshuang, Xie, Qiqi, Guan, Yumei, Liu, Xinlan, Ren, Dengfeng, Zhao, Fuxing, Liu, Zhilin, Ma, Fei, Zhao, Jiuda

“…Although breast cancer treatment has been developed remarkably in recent years, it remains the primary cause of death among women. Immune checkpoint blockade…”
Get more information

Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis by Xin, Yuanfang, Shen, Guoshuang, Zheng, Yonghui, Guan, Yumei, Huo, Xingfa, Li, Jinming, Ren, Dengfeng, Zhao, Fuxing, Liu, Zhen, Li, Zitao, Zhao, Jiuda

“…Some studies have shown that Immune checkpoint inhibitors (ICIs) have a favorable efficacy in advanced triple negative breast cancer (TNBC) patients, but the…”
Get full text

Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment by Shen, Guoshuang, Zhao, Fuxing, Huo, Xingfa, Ren, Dengfeng, Du, Feng, Zheng, Fangchao, Zhao, Jiuda

“…Background This meta-analysis aimed to better elucidate the predictive value of human epidermal growth factor receptor 2 (HER2)-enriched subtype of…”
Get full text

Elevated expression of TUBA1C in breast cancer predicts poor prognosis by Zhao, Yi, Wang, Wenwen, Li, Jinming, Du, Jiarui, Xie, Qiqi, Wang, Miaozhou, Liu, Zhen, Huo, Xingfa, Zhao, Fuxing, Ren, Dengfeng, Zhao, Jiuda, Shen, GuoShuang

“…α1C-tubulin ( TUBA1C ) is a member of the α-tubulin family and has served as a potential biomarker in a variety of cancers in many studies. In this study, the…”
Get full text

Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in ER (+) and/or PR (+) and HER2 (−) Breast Cancer by Du, Feng, Zheng, Fangchao, Han, Ying, Zhao, Jiuda, Yuan, Peng

“…Background: Although intrinsic molecular subtype has been widely used, there remains great clinical heterogeneity of prognosis in the estrogen receptor (ER)-…”
Get full text

The emerging role of hypoxia-inducible factor-2 involved in chemo/radioresistance in solid tumors by Zhao, Jiuda, Du, Feng, Luo, Yang, Shen, Guoshuang, Zheng, Fangchao, Xu, Binghe

“…Highlights • We first summarize the contribution of HIF-2α in chemo/radioresistance in solid tumors. • Studies assessing the roles of HIF-2α on drug resistance…”
Get full text

Long-term survival after neoadjuvant therapy for triple-negative breast cancer under different treatment regimens: a systematic review and network meta-analysis by Liu, Zhilin, Li, Jinming, Zhao, Fuxing, Ren, Dengfeng, Li, Zitao, Chen, Yongzhi, Huang, Shifen, Liu, Zhen, Zhao, Yi, Wang, Miaozhou, Li, Huihui, Xu, ZhengBo, Shen, Guoshuang, Zhao, Jiuda

“…Triple-negative breast cancer (TNBC) is a life-threatening subtype of breast cancer with limited treatment options. Therefore, this network meta-analysis (NMA)…”
Get full text

Comparative efficacy and safety of first-line neoadjuvant treatments in triple-negative breast cancer: systematic review and network meta-analysis by Li, Jinming, Shen, Guoshuang, Wang, Miaozhou, Huo, Xingfa, Zhao, Fuxing, Ren, Dengfeng, Zhao, Yi, Zhao, Jiuda

“…Neoadjuvant treatment options for triple-negative breast cancer (TNBC) are abundant, but the efficacy of different combinations of treatment options remains…”
Get full text

Correlation between mismatch repair and survival of patients with gastric cancer after 5-FU-based adjuvant chemotherapy by Zhao, Fuxing, Li, Enxi, Shen, Guoshuang, Dong, Qiuxia, Ren, Dengfeng, Wang, Miaozhou, Zhao, Yi, Liu, Zhen, Ma, Jinhua, Xie, Qiqi, Liu, Zhilin, Li, Zitao, Gao, Lihong, Zhao, Jiuda

“…Background Almost all adjuvant chemotherapy regimens for gastric cancer recommended by guidelines are fluorouracil (5-FU) based, and 5-FU-based adjuvant…”
Get full text

Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up by Zheng, Fangchao, Du, Feng, Wang, Wenmiao, Wang, Yongsheng, Li, Ming, Zhao, Jiuda, Wang, Xue, Yue, Jian, Wang, Jiayu, Yang, Zixuan, Cai, Ruigang, Ma, Fei, Fan, Ying, Li, Qing, Zhang, Pin, Xu, Binghe, Yuan, Peng

“…Background Paclitaxel/docetaxel after doxorubicin plus cyclophosphamide (ECT) is considered as an adjuvant chemotherapy and improves the survival of early…”
Get full text

Second-line Endocrine Therapy of Hormone Receptor-positive/HER2- negative Advanced Breast Cancer: A Systematic Review and Network Meta-analysis by Wang, Tianzhuo, Shen, Guoshuang, Li, Jinming, Huo, Xingfa, Wang, Miaozhou, Liu, Zhen, Zhao, Fuxing, Ren, Dengfeng, Zhao, Jiuda

“…The optimal second-line therapy for hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast…”
Get more information

The association between HER2-low expression and prognosis of breast cancer: a systematic review and meta-analysis by Tang, Yuyao, Shen, Guoshuang, Xin, Yuanfang, Li, Zhoujuan, Zheng, Yonghui, Wang, Miaozhou, Liu, Zhen, Zhao, Yi, Zhao, Fuxing, Ren, Dengfeng, Zhao, Jiuda

“…Background: The use of antibody–drug conjugates for the treatment of advanced-stage human epidermal growth factor receptor 2 (HER2)-low expression in breast…”
Get full text

Watson for oncology decision system for treatment consistency study in breast cancer by Liu, Yaobang, Huo, Xingfa, Li, Qi, Li, Yishuang, Shen, Guoshuang, Wang, Miaozhou, Ren, Dengfeng, Zhao, Fuxing, Liu, Zhen, Zhao, Jiuda, Liu, Xinlan

“…The Watson for Oncology (WFO) decision system has been rolled out in many cancers. However, the consistency of treatment for breast cancer is still unclear in…”
Get full text

Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China by Yang, Jiao, Zhao, Bing, Ling, Xiaoling, Li, Donghui, Zhao, Jiuda, Lv, Yonggang, Wang, Guangxi, Liu, Xinlan, Li, Nanlin, Yang, Jin

“…Real-world data of Palbociclib are insufficient in China. This study aimed to investigate the treatment pattern and real-world outcomes in hormone receptor…”
Get full text

Cyclin-dependent kinase 4 and 6 inhibitors in combination with neoadjuvant endocrine therapy in estrogen receptor-positive early breast cancer: a systematic review and meta-analysis by Guan, Yumei, Shen, Guoshuang, Fang, Qianqian, Xin, Yuanfang, Huo, Xingfa, Li, Jinming, Zhao, Fuxing, Ren, Dengfeng, Liu, Zhen, Li, Zitao, Zhao, Jiuda

“…The combination of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors and endocrine treatment has benefited patients with estrogen receptor-positive/human…”
Get full text

Treatment options for patients with human epidermal growth factor 2-positive breast cancer brain metastases: A systematic review and meta-analysis by Huo, Xingfa, Shen, Guoshuang, Wang, Tianzhuo, Li, Jinming, Xie, Qiqi, Liu, Zhen, Wang, Miaozhou, Zhao, Fuxing, Ren, Dengfeng, Zhao, Jiuda

“…Many systemic treatment options are available for patients with human epidermal growth factor 2 (HER2)-positive breast cancer brain metastases. However, it is…”
Get full text

Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer by Wang, Guoxiu, Zhao, Jiuda, Song, Yan, Zhang, Wen, Sun, Yongkun, Zhou, Aiping, Huang, Jing, Du, Feng, Yang, Lin

“…S-1 plus oxaliplatin(SOX) has been demonstrated to be effective and well tolerated for patients with metastatic gastric cancer. We conducted this phase II…”
Get full text

Recent advances in glucose oxidase-based nanocarriers for tumor targeting therapy by Li, Su, Wang, Qinghua, Jia, Zhen, Da, Mengting, Zhao, Jiuda, Yang, Rui, Chen, Daozhen

“…Glucose oxidase (GOx) can specifically catalyze the conversion of β-d-glucose into gluconic acid and hydrogen peroxide (H2O2) in the presence of oxygen, making…”
Get full text